HRSA is maintaining an open federal procurement for Medical Case Reviewer Services for the Vaccine Injury Compensation Program (VICP) and Countermeasures Injury Compensation Program (CICP) under solicitation 75R60225Q00181. The current SAM.gov opportunity reflects Amendment P0001 dated August 21, 2026 and a response deadline of August 20, 2031 at 5:00 p.m. EDT. The amendment materials state that the solicitation remains open with no formal closing date, while SAM carries the 2031 response date.
What HRSA is buying
The procurement establishes Blanket Purchase Agreements for medical expert witness and medical case reviewer services supporting VICP/CICP case review and litigation. The published materials describe medical record review, written reports, expert support and, when required, testimony. The parent BPA period is five years, with individual call orders generally running 11 months.
Competition and qualifications
This is a Total Small Business Set-Aside. The SAM record identifies NAICS 621111 and PSC R424; Amendment P0001 also adds NAICS 541611. Medical Case Reviewers must have general medical claims-review experience and at least five years of experience directly reviewing cases related to vaccine administration and vaccine injury. The procurement materials require active SAM registration/UEI and submission items including a signed SF 1449, price quote, CV or resume, Data Collection Form and Non-Disclosure Agreement.
Funding and workload
The BPA documentation states a maximum BPA value of $7.5 million, which is a vehicle ceiling rather than a guaranteed award. Individual orders may vary. Published amendment Q&A materials describe several hundred call orders annually across the program, with notable historical demand for Neurology, Orthopedics and Immunology and typical case reviews of roughly 12 to 15 hours depending on complexity.
Atlas analysis
Atlas Opportunity Score: 62/100. This is a legitimate open clinical-services procurement with a long response horizon and a small-business competition structure, but it is highly specialized. It is not a telehealth, remote-examination, digital-health or equipment opportunity, so the Nonagon N9+ is not a meaningful core fit. A Dr. Miltie or QC Healthcare direct response should proceed only if active SAM/UEI status and the mandatory vaccine-injury case-review qualifications can be documented for the proposed reviewers.
Required next action
Verify active SAM/UEI registration and the mandatory reviewer experience before treating this as a direct Dr. Miltie pursuit. If those qualifications are not available, identify a qualified small-business medical-review partner or hold the opportunity as no-bid. Do not infer reviewer credentials or past performance that are not documented.